|
Mumbai, Oct 7: Wockhardt UK Ltd, the British arm of Indian pharmaceutical major Wockhardt Limited, on Thursday said that the company has sold its Luton plant near London to UK-based Bristol Laboratories. In a media statement, Wockhardt has said that the products of Wallis manufactured earlier at Luton, have been shifted to CP Pharmaceuticals’ plant at Wrexham in Wales, and to Wockhardt’s plants in India.
“We are upgrading the Wales plant as Wockhardt’s largest overseas manufacturing base at an investment of one million pound sterling,” Wockhardt chairman Habil Khorakiwala said. The upgraded Wales plant will eventually become a manufacturing base for Wockhardt’s German subsidiary esparma GmbH. The sale of the Luton plant marks the completion of the restructuring operations after the formation of Wockhardt UK Ltd to integrate the businesses of both Wallis and CP Pharmaceuticals under one banner.
“The sale of the Luton plant will reduce our operating costs and improve the bottomline. Wockhardt UK operations are now fully in sync with the IT, HR, finance and supply chain of Wockhardt headquarters in Mumbai,” Wockhardt UK managing director Sirjiwan Singh said. UK is Wockhardt’s largest market outside India. UK contributes to approximately 35% of Wockhardt’s consolidated revenue. Wockhardt is one of India’s premier research and technology-based pharmaceutical companies and a front-runner in biotechnology. It has a wide global reach and over the past two years it has made two successful acquisitions in Europe and established its own sales and marketing organisations in the US.
Discuss this story on expressindia forums
|
|
 |
 |
 |
About Us | Contact Us | Advertisers | Site Map | Make us your homepage | Work for Us | RSS | Subscribe | Electronic Edition | Privacy Policy© 2010: The Indian Express Limited. All rights reserved throughout the world
